Péter Ferdinandy, MD, PhD, MBA, Founder & CEO of Pharmahungary Group has been noticed as ‘Highly Cited Researcher’ for the 4th time
Budapest, Hungary, 30 November 2021 – Péter Ferdinandy, MD, PhD, MBA, Founder & CEO of Pharmahungary Group, Head of Department of Pharmacology and Pharmacotherapy and Vice-Rector for Science and Innovations of Semmelweis University, Budapest, Hungary has been listed on ‘Highly Cited Researchers 2021’. Clarivative has recently released ‘Highly Cited Researchers’ list for 2021, see www.highlycited.com. In 2021, fewer than 6,700, or about 0.1%, of the world’s researchers, in 21 research fields and across multiple fields, have earned this exclusive distinction. This exceptional research influence is demonstrated by the production of multiple highly-cited papers that rank in the top 1% by citations for field and year in the Web of Science™. Prof. Ferdinandy has been noticed for the 4th time as ‘Highly Cited Researcher’ after 2014, 2017 and 2020. ‘It is a great achievement to get recognized as a highly cited researcher for the fourth time. It is especially important to get noticed in the cross-field category that in my case was achieved by 15 highly-cited scientific publications in the research fields of molecular biology and genetics, clinical medicine, pharmacology, and toxicology. This shows our multidisciplinary approach in drug discovery and drug development, especially in complex diseases such as cardiovascular and metabolic diseases.’ said Péter Ferdinandy, who is considered as one of the worldwide key opinion leaders in the development of therapies for myocardial infarction and cardioprotection.
About Pharmahungary Group
Pharmahungary Group is an ISO 9001:2015 certified Hungarian SME developing innovative in-house R&D projects for valorization and providing preclinical and clinical R&D services since 2003.
• Preclinical R&D services: from in vitro to in vivo studies including custom designed, co-morbidity, and large animal models, e.g. Göttingen minipigs, focusing on but not limited to cardiovascular, metabolic, and renal disease models.
• Clinical R&D services: full management of clinical trials with Medical Devices including In Vitro Diagnostics, ATMPs, Investigator Initiated Trials, and niche trials that need strong scientific and regulatory consulting, e.g. clinical trials on sensitive patient population.